New hope for kidney cancer: ivonescimab trial launches
NCT ID NCT06940518
First seen Jan 15, 2026 · Last updated Jun 23, 2026 · Updated 22 times
Summary
This Phase 2 trial is testing a drug called ivonescimab for people with advanced clear cell renal cell carcinoma (a type of kidney cancer) that has already been treated. The study aims to see if ivonescimab can help control the cancer and to check for side effects. About 40 participants will receive the drug intravenously at MD Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IVONESCIMAB are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivonescimab
What this could lead to
If successful, this could offer a new treatment option for people with advanced kidney cancer that has stopped responding to other therapies.
What could go wrong
This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.